Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 14

775P - Treatment of Kaposi sarcoma with immune-checkpoint inhibitors: A systematic review and single-arm meta-analysis

Date

10 Sep 2022

Session

Poster session 14

Topics

Immunotherapy

Tumour Site

Soft Tissue Sarcomas;  Basal Cell and Squamous Cell Cancers of the Skin

Presenters

Maysa Silveira Vilbert

Citation

Annals of Oncology (2022) 33 (suppl_7): S331-S355. 10.1016/annonc/annonc1058

Authors

M.T. Silveira Vilbert1, I. Hirsch1, E.C. Koch1, T. Pimentel Muniz1, D. Pinheiro Xavier2, M.F. Silva Almeida Ribeiro1, L. Mantle1, S. Saibil1, A. Spreafico1, M.O. Butler1, D. Hogg1

Author affiliations

  • 1 Division Of Medical Oncology And Hematology, Princess Margaret Cancer Centre, M5G 1Z5 - Toronto/CA
  • 2 Instituto De Ciências Da Saúde - Faculdade De Medicina, Universidade Federal do Para-Health Science Institute, 66050-160 - Belém/BR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 775P

Background

Kaposi sarcoma (KS) is a rare cutaneous tumor of endothelial origin, caused by human herpesvirus type 8. Chemotherapy is the standard treatment for KS patients with extensive cutaneous or visceral disease. However, long-term remission is rare. Early phase studies of immune checkpoint inhibitors (ICI) in KS patientshave demonstrated acceptable safety and efficacy profiles. We conducted a systematic review and meta-analysis of efficacy and safety of ICI in patients with KS.

Methods

We searched for clinical trials and observational cohort studies assessing KS patients treated with ICI on PubMed, Scopus, the Cochrane Library, ASCO publications, ESMO, and AACR databases. Efficacy was measured as best overall response rate (BORR), which is defined as the proportion of patients who have a partial (PR) or complete response (CR) to therapy. Heterogeneity was examined with the Cochran Q test and I(2) statistics; p values < 0.05 and I(2) > 25% were considered significant for heterogeneity. We used a DerSimonian and Laird random effects model.

Results

We included five studies: four phase I/II clinical trials and one observational retrospective cohort, for a total of 65 patients. Thirty (46%) patients were HIV-positive, 26 (40%) had classical KS, and 9 (14%) endemic KS. Fifty-six (86%) had previously received at least one systemic treatment for KS. Forty-seven (72%) received single agent anti-PD1 and 18 (28%) the combination of nivolumab 240 mg d1, d15, d28 and ipilimumab 1mg/kg d1 q.42 days. In a pooled analysis, BORR was 58% (95% CI 39 - 77%). Five patients achieved CR, 32 had PR and 2 had sustained stable disease for 24 months. Patients with classic and endemic KS had a BORR of 74% (95% CI 60 - 89%) with a follow-up of >20 months. HIV-related KS patients had a BORR of 44% (95% CI 22 - 65%) with a follow-up range of 3.7 to 5 months. Grade 3 or 4 toxicity were reported in 6/44 patients (13.6%). One patient died of KS herpesvirus associated polyclonal B-cell proliferation.

Conclusions

This single-arm meta-analysis confirms that ICI has anti-tumor activity in patients with KS. Other studies are ongoing and may shed more light on the activity of ICI in KS. Larger phase 3 studies with longer follow up are warranted.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

M.T. Silveira: Financial Interests, Institutional, Funding: Alamos Gold Inc.. E.C. Koch: Financial Interests, Personal, Invited Speaker: Novartis, MSD; Financial Interests, Personal, Advisory Board: Novartis, MSD; Financial Interests, Institutional, Other, Funding: Alamos Gold Inc.; Financial Interests, Institutional, Research Grant: Novartis. T. Pimentel Muniz: Financial Interests, Personal, Research Grant: Novartis; Financial Interests, Institutional, Funding: Alamos Gold Inc.. S. Saibil: Financial Interests, Personal, Advisory Board: Novartis. A. Spreafico: Financial Interests, Personal, Advisory Board: Merck, Bristol Myers Squibb, Oncorus, Janssen, Medison & Immunocore; Financial Interests, Institutional, Research Grant: Novartis, Bristol Myers Squibb, Merck, Bayer, Surface Oncology , Northern Biologics, Janssen Oncology/Johnson & Johnson, Roche, Regeneron, Alkermes, Array Biopharma/Pfizer, GSK, Oncorus, Treadwell, Amgen. M.O. Butler: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, EMD Serono, GlaxoSmithKline, Immunocore, Merck, Novartis, Pfizer, Sanofi; Financial Interests, Institutional, Research Grant: Merck; Financial Interests, Personal, Other, Safety Review Board: Adaptimmune, GlaxoSmithKline. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.